JP2016502974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502974A5 JP2016502974A5 JP2015545914A JP2015545914A JP2016502974A5 JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5 JP 2015545914 A JP2015545914 A JP 2015545914A JP 2015545914 A JP2015545914 A JP 2015545914A JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5
- Authority
- JP
- Japan
- Prior art keywords
- gdc
- combination
- cancer
- acceptable salt
- mehd7945a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734796P | 2012-12-07 | 2012-12-07 | |
| US61/734,796 | 2012-12-07 | ||
| US201361888892P | 2013-10-09 | 2013-10-09 | |
| US61/888,892 | 2013-10-09 | ||
| PCT/US2013/073914 WO2014089570A1 (en) | 2012-12-07 | 2013-12-09 | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502974A JP2016502974A (ja) | 2016-02-01 |
| JP2016502974A5 true JP2016502974A5 (enExample) | 2016-12-15 |
Family
ID=49885413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545914A Pending JP2016502974A (ja) | 2012-12-07 | 2013-12-09 | Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9566334B2 (enExample) |
| EP (1) | EP2928488A1 (enExample) |
| JP (1) | JP2016502974A (enExample) |
| KR (1) | KR20150092760A (enExample) |
| CN (1) | CN104968363A (enExample) |
| BR (1) | BR112015013196A2 (enExample) |
| CA (1) | CA2894153A1 (enExample) |
| HK (1) | HK1211218A1 (enExample) |
| MX (1) | MX2015007054A (enExample) |
| RU (1) | RU2015127037A (enExample) |
| WO (1) | WO2014089570A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX369175B (es) * | 2013-02-25 | 2019-10-30 | Genentech Inc | Métodos para detectar mutantes de akt resistentes a fármacos. |
| IL305639B1 (en) | 2016-08-10 | 2025-10-01 | Hoffmann La Roche | Medicinal products containing Akt protein kinase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| UA95799C2 (en) | 2006-04-26 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Pharmaceutical compounds |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| JP5658565B2 (ja) | 2007-09-12 | 2015-01-28 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法 |
| CN101909631B (zh) | 2007-10-25 | 2012-09-12 | 健泰科生物技术公司 | 制备噻吩并嘧啶化合物的方法 |
| CA2755640C (en) | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
| NZ602084A (en) | 2010-03-11 | 2014-07-25 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| ES2688809T3 (es) * | 2011-04-01 | 2018-11-07 | Genentech, Inc. | Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer |
| WO2012177925A1 (en) * | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| CA2856295A1 (en) * | 2011-11-18 | 2013-05-23 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| JP2015505959A (ja) * | 2011-12-05 | 2015-02-26 | ネステク ソシエテ アノニム | 癌を有する患者に治療を選択する方法 |
-
2013
- 2013-12-09 US US14/649,889 patent/US9566334B2/en not_active Expired - Fee Related
- 2013-12-09 HK HK15112070.1A patent/HK1211218A1/xx unknown
- 2013-12-09 KR KR1020157018031A patent/KR20150092760A/ko not_active Withdrawn
- 2013-12-09 RU RU2015127037A patent/RU2015127037A/ru not_active Application Discontinuation
- 2013-12-09 EP EP13814710.3A patent/EP2928488A1/en not_active Withdrawn
- 2013-12-09 BR BR112015013196A patent/BR112015013196A2/pt not_active Application Discontinuation
- 2013-12-09 CN CN201380072029.4A patent/CN104968363A/zh active Pending
- 2013-12-09 CA CA2894153A patent/CA2894153A1/en not_active Abandoned
- 2013-12-09 MX MX2015007054A patent/MX2015007054A/es unknown
- 2013-12-09 JP JP2015545914A patent/JP2016502974A/ja active Pending
- 2013-12-09 WO PCT/US2013/073914 patent/WO2014089570A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509659A5 (enExample) | ||
| JP2014512354A5 (enExample) | ||
| JP2014512356A5 (enExample) | ||
| RU2013148728A (ru) | Комбинации соединений, ингибирующих акт, и эрлотиниба и способы их применения | |
| MX2021002321A (es) | Nuevos metodos. | |
| JP2014512355A5 (enExample) | ||
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2014509657A5 (enExample) | ||
| RU2012156903A (ru) | Способы комбинированной терапии для лечения пролиферативных заболеваний | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| JP2016528162A5 (enExample) | ||
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| NZ598137A (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| JP2015512398A5 (enExample) | ||
| RU2016141569A (ru) | Комбинации | |
| PH12017501580A1 (en) | Antibody drug conjugates (adc) that bind to flt3 proteins | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| BRPI0916356A2 (enExample) | ||
| MX2014013039A (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. | |
| PH12015500392A1 (en) | Antibody drug conjugates (adc) that bind to 158p1d7 proteins | |
| Kleibeuker et al. | Combining radiotherapy with sunitinib: lessons (to be) learned | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| RU2018138626A (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| RU2015138576A (ru) | Комбинации соединения ингибитора мек с соединением ингибитором her3/egfr и способы применения |